Merck

MerckToday's Merck is a global health care leader working to help the world be well. Merck is known as MSD outside the United States and Canada. Through our prescription medicines, vaccines, biologic therapies and animal health products, we work with customers and operate in more than 140 countries to deliver innovative health solutions. We also demonstrate our commitment to increasing access to health care through far-reaching policies, programs and partnerships.

www.merck.com

Merck RSS Channel

Display # 
Title Published Date
Merck receives Breakthrough Therapy Designation from FDA and PRIME status from EMA for investigational Ebola Zaire vaccine (V920) 26 July 2016
Merck launches Vivera in Latin America 20 January 2016
Merck Acquires IOmet Pharma and expands immuno-oncology development program 11 January 2016
Merck Establishes Joint Venture with Supera Farma 15 February 2012
Merck Publishes 2010 Global Corporate Responsibility Report 03 October 2011
Merck Statement on GARDASIL® 16 September 2011
Merck and Serum Institute Announce Collaboration 12 August 2011
ROTATEQ® (Rotavirus Vaccine, Live, Oral, Pentavalent) Awarded Prix Galien USA 2010 Top Honor 01 October 2010
Merck Receives Approval from FDA for Expanded Indications for Atypical Antipsychotic Medication SAPHRIS® 09 September 2010
Merck Provides New Funding to Fight HIV/AIDS in Botswana 25 August 2010
Single Treatment with ELONVA® Produced Live Birth Rates Comparable to Daily rFSH Injections 30 June 2010
New SIMPONI (Golimumab) Data Shows Sustained Efficacy in the Treatment of Rheumatoid Arthritis 23 June 2010
Merck Announces Launch of Pioneering Collaborative Cancer Trials Network 04 June 2010
Results of the clinical study CALYPSO Published in The Journal of Clinical Oncology 26 May 2010
Merck Positioned to Drive Growth Through Innovative Portfolio, Pipeline and Strategy 12 May 2010
Merck Announces First-Quarter 2010 Financial Results 05 May 2010
Merck Receives CHMP Positive Opinion for New Fertility Treatment, ELONVA® 23 November 2009
New Merck Begins Operations 05 November 2009
Merck and Schering-Plough to Merge 10 March 2009
Two Merck Medicines Recommended for Approval in the European Union 25 April 2008

Most Popular Now

New antibiotic Zavicefta approved i…

AstraZeneca today announced that the European Commission (EC) has granted marketing authorisation for Zavicefta (ceftazidime-avibactam, previously known as CAZ AVI), a ne...

Read more

Novo Nordisk and Aarhus University …

Novo Nordisk and Aarhus University's Science and Technology faculty today signed a collaboration agreement to strengthen protein technology research and development. Unde...

Read more

AstraZeneca enters licensing agreem…

AstraZeneca today announced that it has entered into agreements that support its strategic focus on three main therapy areas; Respiratory, Inflammation and Autoimmunity, ...

Read more

Novartis adds bispecific antibodies…

Today Novartis announced that it has entered into a collaboration and licensing agreement with Xencor for the development of bispecific antibodies for treating cancer. Th...

Read more

Bristol-Myers Squibb and PsiOxus Th…

Bristol-Myers Squibb Company (NYSE: BMY) and PsiOxus Therapeutics, Ltd. (PsiOxus) today announced an exclusive clinical collaboration agreement to evaluate the safety, to...

Read more

Bristol-Myers Squibb acquires Cormo…

Bristol-Myers Squibb Company (NYSE:BMY) and Cormorant Pharmaceuticals announced today that Bristol-Myers Squibb has acquired all of the outstanding capital stock of Cormo...

Read more

Sanofi Pasteur signs research agree…

Sanofi and its vaccines global business unit Sanofi Pasteur announced today a Cooperative Research and Development Agreement with the Walter Reed Army Institute of Resear...

Read more

FDA advances Precision Medicine Ini…

In support of the President’s Precision Medicine Initiative, the U.S. Food and Drug Administration has issued two draft guidances that, when finalized, will provide a fle...

Read more

Merck and Pfizer initiate Phase III…

Merck KGaA, Darmstadt, Germany, and Pfizer (NYSE: PFE) have announced the initiation of a Phase III study, JAVELIN Ovarian 100, to evaluate the efficacy and safety of ave...

Read more

Merck commits €1.5 million to the G…

Merck, a leading science and technology company, today announced it would continue to support the advancement of medical science in the field of fertility through the Gra...

Read more

Laboratory drug trials could lead t…

A new drug with the potential to reverse or slow the development of asthma is being tested by researchers at The University of Queensland. Developed by international phar...

Read more

Twisting and turning to target anti…

Researchers are getting closer to understanding how some natural antibiotics work so they can develop drugs that mimic them. A recent review commissioned by the British g...

Read more

Digest World Pharma Newsletter

Subscribe to our weekly Digest World Pharma Newsletter and stay updated on the latest World Pharma News. Subscribe now, it's free!

Pharmaceutical Companies

[ A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Z ]

© World Pharma News 2006 - 2016